These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34581522)

  • 21. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intention to vaccinate against COVID-19 in Australia.
    Rhodes A; Hoq M; Measey MA; Danchin M
    Lancet Infect Dis; 2021 May; 21(5):e110. PubMed ID: 32941786
    [No Abstract]   [Full Text] [Related]  

  • 25. Perceived Physical and Mental Health and Healthy Eating Habits During the COVID-19 Pandemic in Korea.
    Tuakli-Wosornu YA; Pandiyan U; Stratton C; Hwang Y; Hajjioui A; Muñoz-Velasco LP; Fourtassi M; Cooper R; Balikuddembe JK; Peterson M; Krassioukov A; Palomba A; Tripathi DR; Hong BY
    J Korean Med Sci; 2022 Apr; 37(15):e118. PubMed ID: 35437966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.
    Iqbal Yatoo M; Hamid Z; Parray OR; Wani AH; Ul Haq A; Saxena A; Patel SK; Pathak M; Tiwari R; Malik YS; Sah R; Rabaan AA; Rodriguez Morales AJ; Dhama K
    Hum Vaccin Immunother; 2020 Dec; 16(12):2891-2904. PubMed ID: 32703064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine hesitancy among working-age adults with/without disability in the UK.
    Emerson E; Totsika V; Aitken Z; King T; Hastings RP; Hatton C; Stancliffe RJ; Llewellyn G; Kavanagh A
    Public Health; 2021 Nov; 200():106-108. PubMed ID: 34715531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine hesitancy in the COVID-19 era.
    Adhikari B; Cheah PY
    Lancet Infect Dis; 2021 Aug; 21(8):1086. PubMed ID: 34217431
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of COVID-19 and major adverse clinical outcomes among people with disabilities in South Korea.
    Choi JW; Han E; Lee SG; Shin J; Kim TH
    Disabil Health J; 2021 Oct; 14(4):101127. PubMed ID: 34134944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy.
    Ison MG; Avery R; Blumberg E; Chin-Hong P; Halasa N; Kaul D; Pergam S; Theodoropoulos NM; Wolfe CR
    Transplantation; 2021 Oct; 105(10):e131-e132. PubMed ID: 33724250
    [No Abstract]   [Full Text] [Related]  

  • 34. Exposure to COVID-19 Infection and Mortality Rates Among People With Disabilities in South Korea.
    Jeon WH; Oh IH; Seon JY; Kim JN; Park SY
    Int J Health Policy Manag; 2022 Dec; 11(12):3052-3059. PubMed ID: 35942968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The politics of Covid-19 vaccine confidence.
    Sabahelzain MM; Hartigan-Go K; Larson HJ
    Curr Opin Immunol; 2021 Aug; 71():92-96. PubMed ID: 34237648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making sense of unfamiliar COVID-19 vaccines: How national origin affects vaccination willingness.
    Jensen EA; Wagoner B; Pfleger A; Herbig L; Watzlawik M
    PLoS One; 2021; 16(12):e0261273. PubMed ID: 34965278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2.
    Krsak M; Harry BL; Palmer BE; Franco-Paredes C
    Viral Immunol; 2021 Oct; 34(8):504-509. PubMed ID: 34227891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
    Parry H; Tut G; Bruton R; Faustini S; Stephens C; Saunders P; Bentley C; Hilyard K; Brown K; Amirthalingam G; Charlton S; Leung S; Chiplin E; Coombes NS; Bewley KR; Penn EJ; Rowe C; Otter A; Watts R; D'Arcangelo S; Hallis B; Makin A; Richter A; Zuo J; Moss P
    Elife; 2021 Sep; 10():. PubMed ID: 34586068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.